Completed PHASE1 INTERVENTIONAL 6-arm NCT05217732

Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Randomized, Double-blind and Placebo-controled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ZX-7101A and Its Food Effect in China Healthy Adult Volunteers

Sponsor: Nanjing Zenshine Pharmaceuticals

Conditions Food Effect Pharmacokinetics Safety Issues Tolerance

Interventions Placebo ZX-7101A

Updated 4 times since 2022 Last updated: Jul 20, 2023 Started: Dec 1, 2021 Primary completion: Aug 29, 2022 Completion: Dec 19, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Food Effect and Pharmacokinetics and is currently completed. Nanjing Zenshine Pharmaceuticals leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2022 — Aug 2023 [monthly]

Recruiting PHASE1

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nanjing Zenshine Pharmaceuticals

Data source: Nanjing Zenshine Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China